BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sheu MJ, Hsieh MJ, Chiang WL, Yang SF, Lee HL, Lee LM, Yeh CB. Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS One 2015;10:e0122961. [PMID: 25860955 DOI: 10.1371/journal.pone.0122961] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Sci Rep 2020;10:17054. [PMID: 33051476 DOI: 10.1038/s41598-020-73930-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Kim JH, Jeong SY, Jang HJ, Park ST, Kim HS. FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:762528. [PMID: 34737965 DOI: 10.3389/fonc.2021.762528] [Reference Citation Analysis]
3 Chen TH, Yang SF, Liu YF, Lin WL, Han CP, Wang PH. Association of Fibroblast Growth Factor Receptor 4 Genetic Polymorphisms With the Development of Uterine Cervical Cancer and Patient Prognosis. Reprod Sci 2018;25:86-93. [PMID: 28378614 DOI: 10.1177/1933719117702250] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Kucukoglu O, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol. 2021;74:442-457. [PMID: 33161047 DOI: 10.1016/j.jhep.2020.10.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
5 Chen L, Qi H, Zhang L, Li H, Shao J, Chen H, Zhong M, Shi X, Ye T, Li Q. Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients. BMC Cancer 2018;18:1038. [PMID: 30359238 DOI: 10.1186/s12885-018-4951-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chou CH, Hsieh MJ, Chuang CY, Lin JT, Yeh CM, Tseng PY, Yang SF, Chen MK, Lin CW. Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility. Oncotarget 2017;8:96225-38. [PMID: 29221201 DOI: 10.18632/oncotarget.21958] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
7 Lau HK, Hsieh MJ, Yang SF, Wang HL, Kuo WH, Lee HL, Yeh CB. Association between Interleukin-18 Polymorphisms and Hepatocellular Carcinoma Occurrence and Clinical Progression. Int J Med Sci 2016;13:556-61. [PMID: 27429592 DOI: 10.7150/ijms.15853] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
8 Al-daghri NM, Mohammed AK, Al-attas OS, Draz HM, Alokail MS. Gender-Specific Association Between FGFR4 Gly388Arg Gene Variants and Hypertension. Genetic Testing and Molecular Biomarkers 2017;21:422-7. [DOI: 10.1089/gtmb.2016.0320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Tsay MD, Hsieh MJ, Lee CY, Wang SS, Chen CS, Hung SC, Lin CY, Yang SF. Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma. Int J Environ Res Public Health 2019;17:E129. [PMID: 31878098 DOI: 10.3390/ijerph17010129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Liu Y, Wang C, Li J, Zhu J, Zhao C, Xu H. Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer. Front Pharmacol 2021;12:633453. [PMID: 33981224 DOI: 10.3389/fphar.2021.633453] [Reference Citation Analysis]
11 Xiong SW, Ma J, Feng F, Fu W, Shu SR, Ma T, Wu C, Liu GC, Zhu J. Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis. Oncotarget 2017;8:25300-9. [PMID: 28445975 DOI: 10.18632/oncotarget.15811] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
12 Peng T, Sun Y, Lv Z, Zhang Z, Su Q, Wu H, Zhang W, Yuan W, Zuo L, Shi L, Zhang LF, Zhou X, Mi Y. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer. Sci Rep 2021;11:1373. [PMID: 33446698 DOI: 10.1038/s41598-020-80146-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Moazeni-Roodi A, Sarabandi S, Karami S, Hashemi M, Ghavami S. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer. Biosci Rep 2020;40:BSR20192051. [PMID: 33017009 DOI: 10.1042/BSR20192051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Raja A, Park I, Haq F, Ahn SM. FGF19-FGFR4 Signaling in Hepatocellular Carcinoma. Cells. 2019;8:pii: E536. [PMID: 31167419 DOI: 10.3390/cells8060536] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
15 Dianat-moghadam H, Teimoori-toolabi L. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications. CDT 2019;20:852-70. [DOI: 10.2174/1389450120666190112145409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Khan W, Ahmad W, Hashem AM, Zakai S, Haque S, Malik MFA, Harakeh S, Haq F. Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients. JCM 2022;11:3093. [DOI: 10.3390/jcm11113093] [Reference Citation Analysis]
17 Wang H, Yang J, Zhang K, Liu J, Li Y, Su W, Song N. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets. Front Pharmacol 2021;12:650388. [PMID: 33935756 DOI: 10.3389/fphar.2021.650388] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Chen W, Tang D, Ou M, Dai Y. Mining Prognostic Biomarkers of Hepatocellular Carcinoma Based on Immune-Associated Genes. DNA Cell Biol 2020;39:499-512. [PMID: 32069130 DOI: 10.1089/dna.2019.5099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Li JP, Huang HC, Yang PJ, Chang CY, Chao YH, Tsao TC, Huang H, Hung YC, Hsieh MJ, Yang SF. FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan. Int J Environ Res Public Health 2020;17:E5694. [PMID: 32781755 DOI: 10.3390/ijerph17165694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]